CJC-1295 with DAC vs without DAC: the real differences

Last updated 2026-07-26

What's actually different between CJC-1295 with DAC and without DAC?

The peptide backbone is nearly the same. Both versions are modified analogues of growth hormone releasing hormone (GHRH), built off the first 29 or 30 amino acids of native GHRH with substitutions that resist enzymatic breakdown. The difference that matters is a chemical tail called DAC, short for Drug Affinity Complex, attached to one version and absent from the other. DAC is a maleimide group that covalently binds to a free cysteine on serum albumin once injected. Albumin is the most abundant protein in blood plasma, and once the peptide is locked onto it, the peptide gets protected from enzymatic degradation and cleared much more slowly. That's the entire mechanism behind the difference in dosing schedules. This binding chemistry, and the resulting extended half-life, is what the original human pharmacokinetic study on the DAC-bearing molecule was designed to measure. Without DAC, the peptide is often labeled Modified GRF (1-29), or Mod GRF 1-29, or CJC-1295 no DAC. It's still a GHRH analogue, it still triggers a pulse of growth hormone release from the pituitary, but it clears from circulation on a scale of minutes, consistent with native GHRH's own short half-life ^[1]. With DAC, the same core peptide sits on albumin for days, producing a half-life of roughly 6 to 8 days depending on the study and dose ^[2][3]. See the full mechanism writeup on cjc-1295 if you want the deeper pharmacology before comparing the two forms.

How long does each version actually last in the body?

This is the single biggest practical difference and it's not close. The foundational human trial on the DAC version, published in the Journal of Clinical Endocrinology & Metabolism in 2006, reported a half-life of approximately 5.8 to 8.1 days across dose groups, with GH and IGF-1 elevations sustained for 6 to 11 days after a single injection ^[2]. Without DAC, there isn't a comparably large, long-term published human trial specific to that exact molecule under that exact name. What is well documented is the pharmacokinetics of GHRH(1-29) analogues generally, which clear on a scale of minutes, consistent with native GHRH's own very short half-life in circulation ^[1]. Compounders and gray-market sellers describe the no-DAC version as needing 1 to 3 doses per day to keep GH pulses going, which follows logically from that short half-life, but that specific multi-dose protocol has not itself been tested in a published controlled trial. | Feature | CJC-1295 with DAC | CJC-1295 without DAC (Mod GRF 1-29) |

What does the actual clinical evidence show for each version?

The best human data sits behind the DAC version. Teichman et al. (2006) ran single and multiple-dose studies in healthy adults and found that a single injection of CJC-1295 (with DAC) at doses of 30, 60, 90, or 120 mcg/kg produced dose-dependent increases in GH, with mean GH levels remaining elevated for 6 days at the highest dose and IGF-1 levels increasing by 1.5 to 3 times baseline that persisted for up to 9 to 11 days ^[2]. Multiple dose administration every 7 or 14 days over prolonged periods maintained elevated IGF-1 without evidence of GH desensitization over the study window, according to the same paper's stated conclusions. The no-DAC version doesn't have an equivalent published trial under that name. Most of what circulates is inference from GHRH physiology and forum-reported protocols, not peer-reviewed dosing data. If someone tells you a specific no-DAC injection schedule is "proven," ask for the citation. There usually isn't one for that exact claim. Neither version has gone through an FDA New Drug Application process. Both exist in the research chemical and compounding space, outside any approved indication, which is a separate question from which version has better pharmacokinetic documentation behind it. That distinction, approved versus studied, matters more than choosing between the two forms.

Why do people pair CJC-1295 with ipamorelin, and does the DAC choice change that?

Ipamorelin is a ghrelin-receptor agonist, a different mechanism entirely from a GHRH analogue. GHRH analogues like CJC-1295 tell the pituitary to release more GH; ghrelin mimetics like ipamorelin amplify that release and also suppress somatostatin, the hormone that puts a brake on GH secretion. Combining a GHRH analogue with a ghrelin mimetic is a well-established pharmacological logic in the growth hormone secretagogue literature generally, and studies of other GHRH-plus-GHRP combinations have shown greater GH release than either compound alone ^[4]. That rationale is sound as a mechanism. What it is not is a settled clinical outcome for the CJC-1295-plus-ipamorelin combination specifically. There is no large published trial testing CJC-1295 (with or without DAC) stacked with ipamorelin for a defined health outcome, body composition endpoint, or long-term safety profile. The appeal of pairing them is mostly extrapolated from separate mechanism studies and widely repeated in forum and compounding pharmacy material, which is a different thing from clinical evidence. On the DAC question specifically: people who want a steady, low-maintenance GH pulse tend to reach for CJC-1295 with DAC alongside daily ipamorelin, since the long half-life covers the GHRH side continuously while ipamorelin is dosed once or more per day for its own shorter action. People chasing something closer to a natural GH pulse pattern often use no-DAC CJC-1295 timed right alongside ipamorelin, both short-acting, both dosed together multiple times a day. Neither pattern has a comparative trial behind it. It's a protocol choice built on plausible pharmacology, not outcome data.

How does dosing frequency actually work for each version?

With DAC, published human dosing in the Teichman study used doses from 30 to 120 mcg/kg given as single injections, and a separate multiple-dose arm gave repeat injections every 7 or 14 days ^[2]. That maps to the weekly-injection pattern that most current protocols use. For a full breakdown of common milligram ranges and how they scale by body weight, see CJC-1295 dosage guidance and the DAC dosage calculator, which walks through converting mcg/kg into a practical vial concentration. Without DAC, there is no equivalent published multi-week human dosing trial to point to. The multiple-times-daily pattern common in practice (often timed before meals or before bed, mirroring natural GH pulses) comes from extrapolation off the peptide's short half-life and off older GHRH-analogue research rather than a dedicated trial of this exact formulation. A practical note: because DAC-bound CJC-1295 stays in circulation for days, overlapping doses stack. Injecting it more often than weekly without knowing your clearance rate risks a much higher steady-state GH/IGF-1 elevation than intended, which is one reason most protocols space it out rather than daily.

What are the side effects, and do they differ by DAC status?

The reported side effect profile is similar in kind between the two versions, since both stimulate GH and IGF-1, but the duration of any given side effect differs because of the half-life gap. In the Teichman 2006 trial, injection site reactions, flushing, and transient effects on cortisol and prolactin were reported, and no serious adverse events were noted at the doses tested, according to the paper's own safety reporting ^[2]. Because CJC-1295 with DAC stays active for close to a week, any side effect tied to elevated GH or IGF-1, water retention, joint stiffness, or blood sugar shifts, tends to persist longer per dose than with the no-DAC version, where effects fade within hours. That said, no-DAC users typically inject far more often, so the cumulative exposure over a week can end up similar. For a full rundown of documented and theoretical risks, see CJC-1295 side effects. Neither version has gone through the kind of large-scale, long-term safety trial that would be needed to fully characterize risk, which applies equally to both forms since neither has completed full clinical development.

Is one version more studied or more legitimate than the other?

With DAC has the stronger paper trail. The 2006 JCEM study is the anchor reference almost everyone cites, and it's specific to the DAC-bearing molecule at defined doses in humans ^[2]. That's real, peer-reviewed, dose-ranging pharmacokinetic and pharmacodynamic data, even though it's one study with a modest sample size and short observation window relative to how people use the compound today. Without DAC doesn't have a directly comparable published human trial under that name. What supports it is general GHRH-analogue pharmacology and shorter mechanistic studies on GRF(1-29) itself and native GHRH physiology ^[1], plus a large amount of practitioner and forum-reported experience that is not peer-reviewed and shouldn't be treated as equivalent to a clinical trial. Neither status makes one version "approved" or medically endorsed. Both remain outside FDA-approved indications, and the honest position is that with DAC has better documentation of its pharmacokinetics, while without DAC has a plausible but thinner evidence base specific to itself.

Which one is cheaper or more practical to source?

Pricing swings by supplier and purity claims, but no-DAC CJC-1295 (Mod GRF 1-29) is generally the lower-cost peptide per milligram since it's a smaller, simpler molecule to synthesize, while with-DAC CJC-1295 usually carries a price premium tied to the added conjugation chemistry and its longer, more complex synthesis. The bigger practical driver of total cost is dosing frequency: no-DAC's need for multiple daily injections can offset its lower per-mg price once you tally weekly vial usage against the with-DAC version's once or twice weekly schedule. Sourcing quality control matters more than either of those price differences. Peptides in this category are not regulated the way an FDA-approved drug is, so purity, correct sequence, and endotoxin testing vary a great deal by supplier. If you're comparing options, CJC-1295 for sale covers what to check on a certificate of analysis before buying either form, and provider-reviewed routes that pair you with a fulfilling pharmacy partner are the more accountable path compared to unverified research-chemical vendors. CJC-1295 Co's role here is to point toward that provider-reviewed pathway rather than to compound or sell peptide product directly.

Which version should you actually pick?

If the goal is fewer injections and a steady, sustained IGF-1 lift with the best available human pharmacokinetic data behind it, CJC-1295 with DAC is the more evidence-backed choice for dosing behavior, per the Teichman 2006 findings ^[2]. If the goal is mimicking a more natural, pulsatile GH release pattern and you're willing to inject multiple times a day, no-DAC is the more commonly chosen option, though it rests on thinner, less molecule-specific published evidence. Neither choice is a settled medical recommendation. Both sit outside FDA-approved use, both come from a research literature with real gaps in long-term safety data, and anyone considering either should be doing so under a provider who can review labs, discuss the actual evidence gaps honestly, and monitor IGF-1 and glucose markers over time rather than following an anonymous forum protocol. Start with the mechanism piece on CJC-1295 itself if you haven't, then move to dosage specifics once you've decided which form fits the injection schedule you're actually willing to stick to.

Frequently asked questions

What does DAC stand for in CJC-1295 with DAC?

DAC stands for Drug Affinity Complex. It's a maleimide chemical group attached to the CJC-1295 peptide that binds covalently to a cysteine residue on serum albumin in the blood. That binding protects the peptide from rapid breakdown and stretches its half-life from about 30 minutes to roughly 6-8 days, per the 2006 JCEM pharmacokinetic study ^[1].

Is CJC-1295 without DAC the same as Mod GRF 1-29?

Yes, in common usage. Mod GRF 1-29 (Modified GRF 1-29) is the more accurate name for the shorter peptide sometimes marketed as "CJC-1295 no DAC." It's a modified 29-amino-acid GHRH fragment without the albumin-binding DAC tail, giving it a short circulating half-life on the order of minutes ^[3].

Can you inject CJC-1295 with DAC daily like the no-DAC version?

You could, but it's not how the published dosing was studied and it isn't how most protocols use it. The 2006 human trial dosed the DAC version as single injections or repeats every 7 or 14 days ^[1]. Because it stays bound to albumin for days, daily injection risks compounding GH/IGF-1 exposure well beyond what's been studied.

Does pairing CJC-1295 with ipamorelin work better than either alone?

Mechanistically, combining a GHRH analogue with a ghrelin-receptor agonist like ipamorelin has support from separate studies on GHRH-plus-GHRP combinations showing greater GH release together than alone ^[5]. But there is no large published trial testing CJC-1295 plus ipamorelin specifically, so the combined outcome in humans isn't clinically settled.

Which version raises IGF-1 more, with DAC or without DAC?

The with-DAC version has documented IGF-1 increases of 1.5 to 3 times baseline sustained for up to 9-11 days after a single dose, per Teichman et al. 2006 ^[1]. There's no equivalent published IGF-1 tracking data for the no-DAC version specifically, so a direct comparison isn't available in the literature.

Is CJC-1295 (either version) FDA approved?

No. Neither CJC-1295 with DAC nor without DAC has FDA approval for any indication. Both exist only in research and compounding contexts, and the human pharmacokinetic data behind the DAC version comes from one dose-ranging trial with a modest sample size, not a full drug development program ^[1].

How often do you inject CJC-1295 without DAC?

Common practice describes 1 to 3 injections per day, often timed around meals or before sleep to mirror natural GH pulses, based on the peptide's short, minutes-scale half-life. This specific schedule hasn't been validated in a large published clinical trial under this molecule's name; it's extrapolated from general GHRH pharmacology.

How often do you inject CJC-1295 with DAC?

Published human trial data used single injections and repeat dosing every 7 or 14 days ^[1], which is why most current protocols use once or twice weekly injections. The long albumin-bound half-life of roughly 6-8 days is what allows that spacing.

Which is cheaper, CJC-1295 with DAC or without DAC?

Per milligram, no-DAC CJC-1295 is usually less expensive since it's a simpler molecule to synthesize. But because it requires multiple daily doses versus once or twice weekly for the DAC version, total weekly cost can end up comparable or higher depending on supplier pricing and dose size.

What side effects are reported with CJC-1295?

The 2006 human trial reported injection site reactions, flushing, and transient shifts in cortisol and prolactin, with no serious adverse events at the doses tested ^[1]. Because with-DAC lasts far longer in circulation, any side effect tied to elevated GH or IGF-1 can persist longer per dose compared to the short-acting no-DAC version.

Does CJC-1295 with DAC suppress natural GH pulses?

It changes the pulse pattern rather than mimicking it. Because it stays bound to albumin continuously, it produces a sustained, flattened GH/IGF-1 elevation rather than the sharp natural pulses GHRH normally triggers. Whether this pattern difference has meaningfully different long-term effects than pulsatile release hasn't been tested in a dedicated comparative human trial.

Where can I find real dosing numbers instead of forum guesses?

Start with the primary 2006 JCEM pharmacokinetic study for the DAC version's actual tested doses ^[1], then check CJC-1295 dosage guidance and the DAC dosage calculator for how those figures translate into practical per-body-weight amounts.

Sources

1. Teichman SL, et al., Journal of Clinical Endocrinology & Metabolism, 2006: CJC-1295 with DAC has a half-life of approximately 5.8-8.1 days and sustains GH/IGF-1 elevation for 6-11 days after single dosing
2. National Center for Biotechnology Information, PubMed entry for Teichman 2006 study (PMID 16352683): Multiple-dose CJC-1295 with DAC given every 7 or 14 days maintained elevated IGF-1 over the study period
3. NCBI Bookshelf, StatPearls, Physiology of Growth Hormone-Releasing Hormone: Native GHRH and short GHRH(1-29) analogues have a circulating half-life on the order of minutes
4. U.S. National Library of Medicine, MedlinePlus Genetics/Drug Information context on peptide compounding oversight: Compounded peptide substances outside FDA-approved drug products carry unresolved long-term safety data gaps
5. Growth hormone secretagogue combination pharmacology review, PubMed Central (PMC3040866): Combining a GHRH analogue with a ghrelin-receptor agonist (GHRP) produces greater GH release than either compound given alone
6. U.S. Patent 7,824,685, long-acting growth hormone releasing factor analogs: The DAC albumin-binding conjugation chemistry used to extend CJC-1295's half-life is described in this patent